NEW YORK (GenomeWeb) – Plant genome engineering firm Calyxt announced today that it has priced its planned initial public offering of 7 million shares at $8 per share, for gross proceeds of $56 million.

Calyxt had previously said that it intended to float 6.06 million shares at between $15 and $18 apiece, which would have raised $90.9 million to $109.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.